Document is current

Article History

Received: 7 November 2024

Accepted: 28 February 2025

First Online: 5 June 2025

Declarations

:

: Authors OvV and AB have no competing interests to declare that are relevant to the content of this article. Authors OvV and AB are employed as Associate and Senior Associate, respectively, in the EU Public Affairs Health and Life Sciences Practice of DGA Group (Belgium). Author IdB has no competing interests to declare that are relevant to the content of this article. Author IdB serves as President of the European Dialysis and Transplant Nurses Association/European Renal Care Association (Switzerland). Author DG has no competing interests to declare that are relevant to the content of this article. Author DG serves as President of the European Kidney Patients’ Federation (Spain) and Spanish Kidney Patient Federation (Spain). Author FL is employed as Policy Director for Kidney Care UK and serves as voluntary Chair of the West Hertford Hospital Organ Donation Committee (United Kingdom) and Co-Chair of the stakeholder forum of the Implementation Strategy Group for Organ Utilisation (United Kingdom). Author FL previously served as voluntary Vice Chair of the Lister Hospital Kidney Patient Association (United Kingdom). Author GBP is employed as Chief of the Nephrology Service at Centre Hospitalier Le Mans (France) and serves as Chair of the European Renal Association European Renal Nutrition Group, and as Chair of the Italian Society of Nephrology Conservative Treatment Group (2022 – 2024). Author GBP holds consultantships for Fresenius Kabi, Dr Shahr, and Theradial. Author FW is full-time employed as Principle Scientist in Health Technology by Foundation IMEC the Netherlands (the Netherlands) and holds a part-time position as Associate Professor of Medical Technology within the Nephrology Department of the University Medical Center of Utrecht, co-financed by IMEC and the Dutch Kidney Foundation (the Netherlands). Author FW also serves as voluntary Chair of Working Group 3 “Groundbreaking Innovation” of the European Kidney Health Alliance and as uncompensated Board Member of the Willem Kolff Foundation (the Netherlands). Author FW is also involved with the Neokidney Initiative of the Dutch Kidney Foundation and helped write the international Innovation Roadmap of the US-based Kidney Health Initiative (KHI). Author FW is also affiliated with the ongoing related projects MI-TRAM (funded by a KidneyX Prize), KIDNEW (EU HORIZON-EIC-2022 Pathfinder project 101099092), and NXTGEN HighTech Biomed04 “Artificial Organs” (funded by the Dutch National Governmental Growth Fund). Author RV is an advisor to AstraZeneca, Glaxo Smith Kline, Fresenius Kabi, Novartis, Kibow, Baxter, Nipro, Fresenius Medical Care and Nextkidney.

: Approval from the institutional review board was not required for this article.

: This article does not contain any studies with human participants or animals performed by any of the authors.

: For this retrospective review, formal consent is not required.